CTXR logo

CITIUS PHARMACEUTICALS INC

CTXRNASDAQ
πŸ† #4658 by market capEarnings Dec 21 Β· PostUS Equity
$0.51β–² $0.01 (+2.27%)
Market closed Β· at close
πŸ””
Track CTXR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.3%
7dβ–Ό 5.1%
14dβ–Ό 6.1%
30dβ–² 37.1%
ytdβ–Ό 33.6%
1yβ–Ό 55.2%
🏦Market Cap
$14M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
20.0%
Thin
πŸ’΅FCF Margin
-490.7%
Thin
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.50 – $0.51
52-Week Range
$0.37 – $1.54
Volume (shares)
183,702
Avg Volume (shares)
β€”
Shares Outstanding
27.5M
Next Earnings
2026-12-21

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$1M
P/E Ratio
-0.2
P/S Ratio
2.0x
EPS (TTM)
$-1.77
Dividend Yield
0.00%
Dilution (1yr)
+85.5%
CTXR logo

CITIUS PHARMACEUTICALS INC

CTXR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$39Mβ–Ό βˆ’8.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$27Mβ–Ό βˆ’5.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.5Mβ–² +85.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ–² +$5M YoY
StockOtter Β· stockotter.space

About CITIUS PHARMACEUTICALS INC

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.